Home
Conditions
Hematologic Diseases

Clinical trial condition

Hematologic Diseases

Explore clinical trials studying Hematologic Diseases. Study availability and eligibility vary by location and protocol.

15,344 public trials 2,835 recruiting studies

Refine in advanced search Browse all conditions

Hematologic Diseases trial results

Active, Not Recruiting

Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies

NCT05981209

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations: Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States

View Trial Details

Active, Not Recruiting

Optimizing Induction Chemotherapy Regimens for ND Elderly AML Patients Who Are Eligible for Intense Chemotherapy

NCT06066242

Conditions: Acute Myeloid Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +5 more
Locations: Institute of Hematology & Blood Diseases Hospital Tianjin, China

View Trial Details

Active, Not Recruiting

Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial

NCT05514990

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations: Los Angeles County-USC Medical Center Los Angeles, California, United States

USC / Norris Comprehensive Cancer Center Los Angeles, California, United States

View Trial Details

Active, Not Recruiting

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

NCT03844048

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Blood Protein Disorders, +31 more
Locations: University of Arizona Cancer Center - Tucson /ID# 210548 Tucson, Arizona, United States

UCLA Santa Monica Hematology Oncology /ID# 210551 Los Angeles, California, United States

Ingalls Memorial Hosp /ID# 210553 Harvey, Illinois, United States

Dana-Farber Cancer Institute /ID# 215360 Boston, Massachusetts, United States

View all 56 locations

View Trial Details

Active, Not Recruiting

Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)

NCT06400225

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +19 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, Not Recruiting

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

NCT05497804

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations: Mayo Clinic in Arizona Scottsdale, Arizona, United States

Mayo Clinic Jacksonville, Florida, United States

Mayo Clinic in Rochester Rochester, Minnesota, United States

View Trial Details

Active, Not Recruiting

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L)

NCT06385496

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +19 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, Not Recruiting

National Cancer Institute "Cancer Moonshot Biobank"

NCT04314401

Conditions: Acute Myeloid Leukemia, Adnexal Diseases, Anatomic Stage III Breast Cancer AJCC v8, +98 more
Locations: Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis Daphne, Alabama, United States

Thomas Hospital Fairhope, Alabama, United States

Mobile Infirmary Medical Center Mobile, Alabama, United States

Gulf Health Hospitals Inc/Infirmary Cancer Care - Saraland Saraland, Alabama, United States

View all 150 locations

View Trial Details

Active, Not Recruiting

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)

NCT06390865

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +19 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, Not Recruiting

Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy

NCT05583552

Conditions: Acute Myeloid Leukemia, Bone Marrow Diseases, Hematologic Diseases, +7 more
Locations: Royal Adelaide Hospital Adelaide, Australia

Royal Brisbane and Women's Hospitals Brisbane, Australia

Linear Clinical Research Nedlands, Australia

CHU Nantes - Hôtel Dieu Nantes, France

View Trial Details

Hematologic Diseases

Hematologic Diseases trial results

Related conditions